RecruitingNCT06587100

Wearable Activity Tracking to Curb Hospitalizations

Wearable Activity Tracking to Curb Hospitalizations (WATCH)

Sponsor

University of California, San Francisco

Enrollment

260 participants

Start Date

Apr 7, 2025

Study Type

OBSERVATIONAL

Conditions

Malignant Solid Neoplasm Hematopoietic Neoplasm Lymphatic System Neoplasm

Summary

This study is being done to collect patient generated health data to predict the risk of patients needing emergency department visits or hospitalization before, during. and after receiving radiation therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Apple HealthKit-based devices and a medical device called Fitbit for people with hematopoietic neoplasm, lymphatic system neoplasm, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEFitbit

Participants will wear Fitbit device

DEVICEApple HealthKit-based devices

Participants will wear personal device and share data with study team.

Locations(1)

University of California, San Francisco

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06587100

Related Trials

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

NCT06126276188 locations

Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation

NCT072355011 location

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

NCT06513962205 locations

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

NCT050923731 location

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

NCT038192961 location